Literature DB >> 28771973

Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis.

Gulsen Ozen1, Diane L Kamen2, Ted R Mikuls3, Bryant R England3, Frederick Wolfe4, Kaleb Michaud5.   

Abstract

OBJECTIVE: To profile osteoporosis (OP) care in patients with rheumatoid arthritis (RA) over the past decade.
METHODS: Patients with RA or osteoarthritis (OA) were followed from 2003 through 2014. OP care was defined as receipt of OP treatment (with the exception of calcium/vitamin D) or screening (OPTS). Adjusted trends over followup, and the factors associated with OP care, were examined using multivariable Cox proportional hazards.
RESULTS: OPTS was reported in 67.4% of 11,669 RA patients and in 64.6% of 2,829 OA patients during a median (interquartile range) 5.5 (2-9) years of followup. In patients for whom treatment was recommended by the 2010 American College of Rheumatology (ACR) glucocorticoid-induced OP (GIOP) guidelines (48.4% of RA patients and 17.6% of OA patients), approximately 55% overall reported OP medication use. RA patients were not more likely to undergo OPTS compared to OA patients (hazard ratio 1.04 [95% confidence interval 0.94-1.15]). Adjusted models showed a stable trend for OPTS between 2004 and 2008 compared to 2003, with a significant downward trend after 2008 in both RA and OA patients. Factors associated with receipt of OP care in RA patients were older age, postmenopausal state, prior fragility fracture or diagnosis of OP, any duration of glucocorticoid treatment, and use of biologic agents.
CONCLUSION: Approximately half of RA patients for whom treatment was indicated never received an OP medication. OP care in RA patients was not better than in OA patients, and the relative risk of the application of this care has been decreasing in RA and OA patients since 2008 without improvement after the release of the 2010 ACR GIOP guideline.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28771973      PMCID: PMC5797515          DOI: 10.1002/acr.23331

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  44 in total

1.  Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.

Authors:  Jeffrey R Curtis; Andrew O Westfall; Jeroan Allison; Angela Becker; Mary Elkins Melton; Allison Freeman; Catarina I Kiefe; Marilyn MacArthur; Theresa Ockershausen; Emily Stewart; Norm Weissman; Kenneth G Saag
Journal:  Arch Intern Med       Date:  2007-03-26

2.  Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis.

Authors:  Takefumi Furuya; Takayuki Hosoi; Seiji Saito; Eisuke Inoue; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2011-04-13       Impact factor: 2.980

3.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

4.  Trends in prevention of glucocorticoid-induced osteoporosis.

Authors:  Kenneth G Saag; Stephen H Gehlbach; Jeffrey R Curtis; Thomas E Youket; Karen Worley; Jeffrey L Lange
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

Review 5.  Comorbidities in rheumatoid arthritis.

Authors:  Kaleb Michaud; Frederick Wolfe
Journal:  Best Pract Res Clin Rheumatol       Date:  2007-10       Impact factor: 4.098

6.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 7.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Authors:  Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

8.  Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis.

Authors:  A Gough; P Sambrook; J Devlin; A Huissoon; C Njeh; S Robbins; T Nguyen; P Emery
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

9.  Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.

Authors:  Jeffrey R Curtis; Leslie A McClure; Elizabeth Delzell; Virginia J Howard; Eric Orwoll; Kenneth G Saag; Monika Safford; George Howard
Journal:  J Gen Intern Med       Date:  2009-06-24       Impact factor: 5.128

10.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

View more
  5 in total

Review 1.  Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.

Authors:  Giovanni Adami; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2019-05-23       Impact factor: 4.592

Review 2.  Opportunistic Screening for Osteoporosis Using Computed Tomography: State of the Art and Argument for Paradigm Shift.

Authors:  Leon Lenchik; Ashley A Weaver; Robert J Ward; John M Boone; Robert D Boutin
Journal:  Curr Rheumatol Rep       Date:  2018-10-13       Impact factor: 4.592

Review 3.  Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis.

Authors:  Bernardo D'Onofrio; Michele di Lernia; Ludovico De Stefano; Serena Bugatti; Carlomaurizio Montecucco; Laura Bogliolo
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

Review 4.  Osteoporosis in Rheumatic Diseases.

Authors:  Giovanni Adami; Angelo Fassio; Maurizio Rossini; Cristian Caimmi; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

Review 5.  Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.

Authors:  Yoshiya Tanaka
Journal:  J Clin Med       Date:  2021-03-17       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.